Pulmonary embolism: what does the new AHA/ACC 2026 guide add

Area of Science:

• Cardiology
• Pulmonary Medicine
• Clinical Guidelines

Background:

• The 2026 American Heart Association (AHA)/American College of Cardiology (ACC) Guideline for Evaluation and Management of Acute Pulmonary Embolism (PE) in Adults has been published.
• Critical evaluation of significant guideline sections is necessary for clinical practice.
• Existing guidelines require updates to reflect current evidence and clinical challenges in acute PE management.

Purpose of the Study:

• To critically evaluate key sections of the 2026 AHA/ACC Acute PE Guideline.
• To assess the implications of the new risk stratification for acute PE patients.
• To review the recommended anticoagulant and reperfusion therapies for acute PE.

Main Methods:

• Critical appraisal of the published 2026 AHA/ACC Acute PE Guideline.
• Analysis of the guideline's risk classification system.
• Review of recommendations for anticoagulant and reperfusion therapies.

Main Results:

• The guideline introduces a granular risk classification for acute PE, which requires further validation.
• The guideline endorses low-molecular-weight heparins and direct oral anticoagulants as preferred treatments for most acute PE patients.
• The guideline suggests reperfusion therapies in situations lacking strong scientific evidence.

Conclusions:

• The new risk classification in the 2026 AHA/ACC Acute PE Guideline offers potential benefits but needs validation.
• Current anticoagulant recommendations align with established best practices for acute PE management.
• Further clinical trial data are essential to define precise indications for reperfusion therapies in acute PE.